Form 4: Arcellx Chief Medical Officer Christopher Heery Executes Stock Option and Sells Shares
SEC Form 4 Filing
Christopher Heery, Chief Medical Officer of Arcellx, Inc., exercised a stock option and sold shares of common stock on August 16, 2024, according to a Form 4 filing with the SEC.
Summary
- On August 16, 2024, Christopher Heery, the Chief Medical Officer of Arcellx, Inc. (ACLX), exercised a stock option to acquire 5,450 shares of common stock at a price of $6.28 per share.
- He also sold 5,450 shares of common stock at a weighted average price of $65.0507, within a price range of $65.00 to $65.19.
- These transactions were executed pursuant to a Rule 10b5-1 trading plan established on December 22, 2023.
- Following these transactions, Heery directly owns 9,278 shares of Arcellx common stock and holds options for 49,055 shares.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reports routine insider trading activity. The transactions are part of a pre-planned trading strategy, suggesting no immediate cause for alarm or excessive optimism.
Industry Context
Form 4 filings are standard disclosures required by the SEC when corporate insiders, like officers and directors, trade their company's stock. These filings provide transparency into insider transactions and are closely watched by investors for signals about a company's prospects.
Comparison to Industry Standards
- Insider trading activity is common across publicly traded companies, and Form 4 filings are a standard part of regulatory compliance.
- The use of Rule 10b5-1 trading plans is a common practice among corporate insiders to avoid accusations of trading on non-public information; companies like Amgen, Gilead, and Regeneron all have executives who utilize similar plans.
- The size and frequency of insider transactions can vary widely depending on the individual's compensation structure, stock ownership, and personal financial planning.
Stakeholder Impact
- The transactions may have a minor impact on shareholders as they provide insight into management's perspective on the company's stock.
- The use of a 10b5-1 plan suggests a planned and orderly approach to stock transactions, which can reassure investors.
Key Dates
| Date | Description |
|---|---|
| 2021-04-26 | Vesting Commencement Date for the stock options. |
| 2023-12-22 | Date of entry into Rule 10b5-1 trading plan. |
| 2024-08-16 | Date of stock option exercise and stock sale. |
| 2024-08-19 | Date of signature on the Form 4 filing. |
| 2031-06-09 | Expiration date of the stock option. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.